Short Interest in Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) Decreases By 25.0%

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) was the recipient of a significant decline in short interest in March. As of March 15th, there was short interest totalling 9,600 shares, a decline of 25.0% from the February 28th total of 12,800 shares. Currently, 1.5% of the company’s stock are short sold. Based on an average trading volume of 44,100 shares, the days-to-cover ratio is currently 0.2 days.

Titan Pharmaceuticals Stock Down 4.1 %

Titan Pharmaceuticals stock opened at $3.53 on Tuesday. The firm has a 50 day moving average price of $3.67 and a 200-day moving average price of $3.97. Titan Pharmaceuticals has a twelve month low of $3.03 and a twelve month high of $14.80. The company has a market capitalization of $3.23 million, a P/E ratio of -0.68 and a beta of 1.19.

Titan Pharmaceuticals (NASDAQ:TTNP) last released its earnings results on Thursday, March 20th. The specialty pharmaceutical company reported ($0.85) earnings per share (EPS) for the quarter.

Wall Street Analysts Forecast Growth

Separately, StockNews.com assumed coverage on shares of Titan Pharmaceuticals in a report on Tuesday, March 25th. They set a “sell” rating for the company.

Titan Pharmaceuticals Company Profile

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.